Advanced search
Publication Cover
Future Oncology Volume 19, 2023 - Issue 2
Submit an article Journal homepage
5,159
Views
7
CrossRef citations to date
0
Altmetric
Clinical Trial Protocol

LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy

Robert J Motzer1 Memorial Sloan Kettering Cancer Center,New York,NY 10065,USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6925-2327View further author information
ORCID Icon,
Manuela Schmidinger2 Medical University of Vienna,Vienna,1090,AustriaView further author information
,
Masatoshi Eto3 Kyushu University Hospital,Fukuoka,812-8582,JapanView further author information
,
Cristina Suarez4 Medical Oncology,Vall d’Hebron Institute of Oncology (VHIO),Vall d’Hebron University Hospital,Vall d’Hebron Barcelona Hospital Campus,Barcelona,08035,SpainView further author information
,
Robert Figlin5 Cedars-Sinai Medical Center,Los Angeles,CA 90048,USAView further author information
,
Yanfang Liu6 Merck & Co., Inc.,Rahway,NJ 07065,USAView further author information
,
Rodolfo Perini6 Merck & Co., Inc.,Rahway,NJ 07065,USAView further author information
,
Yayan Zhang6 Merck & Co., Inc.,Rahway,NJ 07065,USAView further author information
&
Daniel YC Heng7 Tom Baker Cancer Centre,Calgary,AB T2N 4N2,CanadaView further author information
 show all
Pages 113-121 | Received 12 Aug 2022, Accepted 08 Dec 2022, Published online: 08 Feb 2023

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Haiyang Yan, Zhaohui Xing, Shuai Liu, Peng Gao & Guiying Guo. (2024) What factors may affect the effect of ICI-combined therapy in patients with metastatic renal cell carcinoma? A meta-analysis. Immunopharmacology and Immunotoxicology 0:0, pages 1-17.
Read now

Articles from other publishers (6)

Charles B. Nguyen, Eugene Oh, Piroz Bahar, Ulka N. Vaishampayan, Tobias Else & Ajjai S. Alva. (2024) Novel Approaches with HIF-2α Targeted Therapies in Metastatic Renal Cell Carcinoma. Cancers 16:3, pages 601.
Crossref
Jiayu Liu, Ying Jiang, Lingyan Chen, Zhiwen Qian & Yan Zhang. (2024) Associations between HIFs and tumor immune checkpoints: mechanism and therapy. Discover Oncology 15:1.
Crossref
Tomokazu Sazuka, Yuto Matsushita, Hiroaki Sato, Takahiro Osawa, Nobuyuki Hinata, Shingo Hatakeyama, Kazuyuki Numakura, Kosuke Ueda, Takahiro Kimura, Masayuki Takahashi, Hajime Tanaka, Yoshihide Kawasaki, Toshifumi Kurahashi, Takuma Kato, Kazutoshi Fujita, Makito Miyake, Takahiro Kojima, Hiroshi Kitamura, Hideaki Miyake & Tomohiko Ichikawa. (2023) Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study. Scientific Reports 13:1.
Crossref
Regina Barragan-Carrillo, Ameish Govindarajan, Adam Rock, Rubens C. Sperandio & Sumanta K. Pal. (2023) Managing Metastatic Renal Cell Carcinoma after Progression on Immunotherapy. Hematology/Oncology Clinics of North America 37:5, pages 965-976.
Crossref
Vincenzo Formica, Silvia Riondino, Cristina Morelli, Simona Guerriero, Federica D’Amore, Antonio Di Grazia, Giovanna Del Vecchio Blanco, Giuseppe Sica, Hendrik-Tobias Arkenau, Giovanni Monteleone & Mario Roselli. (2023) HIF2α, Hepcidin and their crosstalk as tumour-promoting signalling. British Journal of Cancer 129:2, pages 222-236.
Crossref
Claire Masson, Jonathan Thouvenin, Philippe Boudier, Denis Maillet, Sabine Kuchler-Bopp, Philippe Barthélémy & Thierry Massfelder. (2023) Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma. Cancers 15:12, pages 3159.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.